CagriSema, which underperformed expectations in its first Phase 3 test, will be studied at different doses and for longer ...

Avalere Health , a global strategic healthcare partner, announces a new commitment to make EVERY PATIENT POSSIBLE. The ...

Revenue for Arexvy and Abrysvo fell sharply year over year in the fourth quarter due to narrower U.S. guidelines for their use.

Analysts said the move comes amid rising trade tensions with the U.S. and as Illumina faces stiff competition in China’s genome sequencing market.

The FDA has paused a study of Amgen’s early-stage candidate AMG 513. Elsewhere, Valneva got another approval and a radiopharma developer raised $112 million.

Sen. Bill Cassidy, whose “yes” vote advanced Kennedy’s nomination as health secretary, said Kennedy promised to maintain ACIP ...

Flagship’s Pioneering Medicines initiative could acquire Omega’s assets via a stalking horse bid, according to a regulatory ...

After decades of research, Vertex Pharmaceuticals now has an approved pain medication. Can one of the world’s most powerful ...

Louisiana Sen. Bill Cassidy joined his Republican colleagues in voting to advance Kennedy's nomination to a vote by the full ...

The results could sway U.S. regulators to convert Braftovi’s accelerated clearance in colorectal tumors into a full approval ...

DiveWire guarantees visibility for your news announcements through instant distribution to BioPharma Dive’s audience and its 176,000 newsletter subscribers for 21 days.

Executives pulled back on a 2030 sales target of $11 billion as demand for the HPV shot shrinks amid China market turmoil.